Abstract
Capitalizing on bacteria's natural capacity to infiltrate tumor microenvironments, bacterial cancer therapy offers a fresh paradigm for targeting solid tumors. Bacterial cancer therapies have a unique mechanism to cure cancer that is unachievable with current methods. This article addresses the possibility for "Microbial Mavericks," or bacteria, to accumulate specifically in cancerous tissues by taking advantage of the special characteristics of tumors’ micro-environment including hypoxia and acidity. Bacteria can be simply genetically modified to develop and deliver anticancer agents according to clinical needs. Researchers want to improve therapeutic efficacy while reducing systemic negative effects by utilizing bacteria's tumor tropism. The need to carefully weigh the potential advantages of bacterial therapeutics with the risks of infections, immunological reactions, and bacterial resistance is emphasized, along with safety issues and challenges. Over the last decades, Salmonella, Clostridium, Listeria, and many other genera have been researched to inhibit cancer growth and increase survival in animal models. This manuscript provides insights into the potential, challenges, and ethical ramifications of the developing field of bacterial cancer therapy. The symbiotic interaction between bacteria and tumors may usher in a new era of cancer treatment as clinical research advances, leveraging the strength of microbial allies in the battle against cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.